Health
GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
- Blenrep reduced risk of death in trial, said British drugmaker
- GSK predicts annual sales of over £3 billion if approved
This article is for subscribers only.
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another treatment, further boosting the prospects of bringing the previously withdrawn medicine back to market.
Blenrep helped patients whose myeloma has relapsed to live longer when combined with cancer therapy BorDex. The British drugmaker said Thursday the results of the late-stage trial are “potentially transformative” for patients. The data on Blenrep is likely to change how some patients with myeloma are treated, said GSK Chief Commercial Officer Luke Miels.